Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Oncotype DX Stories

2013-05-01 16:30:36

Complete Results from UCSF-Led Validation Study to be Presented Earlier that Day at the American Urological Association (AUA) Annual Meeting in San Diego REDWOOD CITY,Calif., May 1, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will host an investor webcast and conference call to discuss the positive development and clinical validation study results of its biopsy-based Oncotype DX prostate cancer test on Wednesday, May 8, 2013 at...

2013-04-25 08:34:45

REDWOOD CITY, Calif., April 25, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Thursday, May 2 at 4:30 p.m. Eastern Time to discuss its first quarter 2013 financial results. The call and webcast will follow the release of the first quarter financial results after market close. (Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO) Conference Call Details To access the live conference call on...

2013-04-17 08:26:36

Findings of CALGB 9581 Published in the Journal of Clinical Oncology Support Expansion of Colon Cancer Reimbursement and Broader Patient Access REDWOOD CITY, Calif., April 17, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the Journal of Clinical Oncology (JCO) published positive results from the large CALGB 9581 clinical validation study of the Oncotype DX® colon cancer test in stage II colon cancer patients. The findings provide further...

2013-04-03 08:27:52

Complete Results from Positive Clinical Validation Study to be Presented at 2013 American Urological Association (AUA) Annual Meeting REDWOOD CITY, Calif., April 3, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the clinical trial results validating its biopsy-based Oncotype DX® prostate cancer test will be presented by investigators from the University of California, San Francisco (UCSF) in an oral session at the American Urological Association...

2013-03-15 08:26:42

New Findings Emphasize Oncotype DX's Real-life Impact for Patients and Physicians and Reduction in Healthcare Costs, Underscore Value of Broader Access for All Patients REDWOOD CITY, Calif. and ST. GALLEN, Switzerland, March 15, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of results from 22 studies at the 13(th) St. Gallen International Breast Cancer Conference highlighting the impact of the Oncotype DX® breast cancer test around...

2013-03-13 08:33:48

Findings suggest value of Oncotype DX in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy REDWOOD CITY, Calif., March 13, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results of a large study that demonstrates the Oncotype DX® Recurrence Score® result to be a robust predictor of loco-regional recurrence (LRR) in node-positive (N+), estrogen receptor (ER) positive...

2013-02-25 08:29:02

Results Presented at the 14th Annual Advances in Genome Biology and Technology Meeting Reveal Novel Method for RNA-Sequencing and Mutation Identification REDWOOD CITY, Calif., Feb. 25, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the results of two studies demonstrating that DNA strand-of-origin information can help further refine the identification of prognostic biomarkers, and that tumor specific gene mutations can be effectively examined using...

2013-02-06 16:26:25

REDWOOD CITY, Calif., Feb. 6, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter and year ended December 31, 2012. Total revenue for the fourth quarter of 2012 increased to $60.4 million, compared with $53.4 million in the fourth quarter of 2011. Product revenue was $60.0 million in the fourth quarter of 2012, compared with $53.2 million for the fourth quarter of 2011, an increase of 13 percent. Net income in...

2013-01-23 08:28:57

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of the Oncotype DX(®) Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium, including new data demonstrating that Recurrence Score(®) (RS) results changed treatment recommendations in 45 percent of the enrolled stage II colon cancer patients. Presentations also include positive findings from a second health economics analysis suggesting...

2012-12-21 08:23:15

REDWOOD CITY, Calif., Dec. 21, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Kim Popovits, Genomic Health's Chairman, Chief Executive Officer, and President will present at the 31(st) Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 7 at 1:30 p.m. Pacific Time (PT). To access the live and subsequently archived webcast of the presentation, visit the Investor Relations section of Genomic Health's website at...